Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2025-12-25 @ 2:38 AM
NCT ID:
NCT06346834
Eligibility Criteria:
Inclusion Criteria:
* (1) Healthy infants of ≤ 12 months of age;
* (2) Can provide proof of legal identity;
* (3) Have completed two doses of sIPV vaccination at Beijing Institute;
* (4) Able to provide proof of sIPV vaccination;
* (5) The participant's guardian can understand and agree to sign the informed consent form.
Exclusion Criteria:
* (1) Known severe allergy to vaccines or vaccine components, such as urticaria, dyspnea, angioneurotic edema;
* (2) Received immunoglobulins or other blood products, or plan to receive such treatment during the study;
* (3) Received ≥14 days of immunosuppressive or other immunomodulatory therapy or cytotoxic therapy, or plan to receive such therapy during the study;
* (4) Received another investigational vaccine within 28 days before receiving the study vaccine;
* (5) Received a live attenuated vaccine within 14 days before receiving the trial vaccine;
* (6) Received a subunit or inactivated vaccine within 7 days before receiving the trial vaccine;
* (7) Acute exacerbation of various acute illnesses or chronic diseases within the last 7 days;
* (8) Those who had a fever with an axillary temperature \>37.0°C before receiving the study vaccine;
* (9) Participants who, in the judgment of the investigator, have any other factors that make them unsuitable for participation in the study.
Healthy Volunteers:
True
Sex:
ALL
Maximum Age:
12 Months
Study:
NCT06346834
Study Brief:
Protocol Section:
NCT06346834